2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030
Cardiovascular disease is the leading cause of death in women. Decades of grassroots
campaigns have helped to raise awareness about the impact of cardiovascular disease in …
campaigns have helped to raise awareness about the impact of cardiovascular disease in …
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
AR Lyon, T López-Fernández, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
P Garcia-Pavia, C Rapezzi, Y Adler, M Arad… - European heart …, 2021 - academic.oup.com
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease: the Task Force on sports cardiology and exercise in patients with …
or therapeutic medical strategies. However, the ESC Guidelines do not override in any way
whatsoever the individual responsibility of health professionals to make appropriate and …
whatsoever the individual responsibility of health professionals to make appropriate and …
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools …
AR Lyon, S Dent, S Stanway, H Earl… - European journal of …, 2020 - Wiley Online Library
This position statement from the Heart Failure Association of the European Society of
Cardiology Cardio‐Oncology Study Group in collaboration with the International Cardio …
Cardiology Cardio‐Oncology Study Group in collaboration with the International Cardio …
[HTML][HTML] European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A Hochhaus, M Baccarani, RT Silver, C Schiffer… - Leukemia, 2020 - nature.com
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology W orking G roup on M yocardial and P ericardial D …
P Garcia‐Pavia, C Rapezzi, Y Adler… - European journal of …, 2021 - Wiley Online Library
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …